Last update May 13, 2019
We do not have alternatives for Urofollitropin.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Urofollitropin is also known as
Urofollitropin in other languages or writings:
Urofollitropin belongs to this group or family:
Main tradenames from several countries containing Urofollitropin in its composition:
|Tmax||21 ± 9||hours|
|T½||50 - 70||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Follicle stimulating hormone (FSH) or follitropin is a hormone of the gonadotropin type, which is found normally in the body. It is synthesized and secreted by gonadotroph cells from the anterior part of the pituitary gland.
FSH regulates pubertal maturation. In women, it matures the oocytes of the ovary and stimulates the production of estradiol (estrogen hormone). In men it regulates the production of sperm.
UROFOLLITROPIN is a human follitropin derived from purified human menopausal gonadotropin (HMG). Other follitropins are obtained by recombinant engineering (follitropin alpha, beta and delta) with similar uses and effectiveness (Weiss 2019, Taketani 2010, Baker 2009).
It is used in infertility treatments (including polycystic ovary syndrome) to induce ovulation in anovulatory patients who do not respond to clomiphene and for the development of multiple follicles (ovarian hyperstimulation) in ovulatory patients in assisted reproduction programmes.
Subsequently, human chorionic gonadotropin (hCG) is usually administered to trigger ovulation.
Subcutaneous or intramuscular administration of a daily dose with ovarian ultrasound monitoring, for 7 to 14 days according to evolution.
Since the last update we have not found published data on its excretion in breastmilk.
Its high molecular weight makes its excretion in breastmilk very unlikely.
Due to its proteinaceous nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability is practically zero), which impedes transfer to infant plasma from breastmilk, except in premature babies and the immediate neonatal period, when there may be more intestinal permeability.
There is no proof that its estrogenic effects decrease milk production.
BREASTFEEDING and INFERTILITY TREATMENTS
In assisted reproduction treatments (ART) for infertility, two issues must be taken into account:
1. The possible effects of ART on the infant or breastfeeding.
The medication used, in general, does not interfere with breastfeeding and does not affect the infant, who in these cases is usually older than 6 months and even 1 or 2 years old.
2. The possible interference of breastfeeding with ART.
Breastfeeding, especially frequent, could hinder ovulation. This is the main reason why assisted reproduction services recommend suspending breastfeeding before starting treatment which is usually emotionally costly and, often, also from a financial perspective.
To date, there is no published data that proves that breastfeeding is incompatible with assisted reproduction techniques (ART).
See below the information of these related products: